Accueil > Actualité
Actualite financiere : Actualite bourse

Novartis: positive trial results in chronic myeloid leukemia

( - Novartis has presented positive results from the 'ASC4FIRST' trial at the ASCO 2024 meeting.

The trial showed that Scemblix, a drug to treat chronic myeloid leukemia, achieved higher major molecular response (MMR) rates than standard therapies in newly diagnosed patients.

The results also demonstrated a favourable safety profile for Scemblix, says the company.

These results have been submitted to the FDA for review, and Scemblix has received Breakthrough Therapy designation.

Copyright (c) 2024 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.